Literature DB >> 6376141

Diltiazem and verapamil: functional antagonism of exogenous noradrenaline and angiotensin II in man.

D Magometschnigg, H Hörtnagl, H Rameis.   

Abstract

To evaluate the possible functional antagonism of the calcium antagonists diltiazem and verapamil of the sympathetic nervous system and the renin-angiotensin system, their influence on blood pressure, heart rate, plasma catecholamines and renin activity (PRA), and on the reaction of these parameters to exogenous noradrenaline (NA) and angiotensin II, was investigated in 8 normotensive volunteers. Intravenous diltiazem or verapamil caused a sharp, shortlasting decrease in systolic and diastolic blood pressure, with a maximum 1-3 min after injection and a duration of 10-15 min. Even a further infusion of the calcium antagonists was unable to maintain the initial hypotensive effect. The cessation of the hypotensive effect was not due to reflex stimulation of the sympathetic nervous system, as indicated by unchanged plasma NA and adrenaline levels in the case of diltiazem, but was associated with an increase in PRA. During the administration of diltiazem and verapamil, the increase in blood pressure in response to the infusion of NA and angiotensin II was attenuated; the increase in diastolic pressure was mainly affected. The inhibition was more pronounced at the higher infusion rate of NA and angiotensin II. On the basis of these findings it is suggest that the hypotensive activity of calcium antagonists can be at least partly attributed to a reduction in vascular tone which is maintained by the postjunctional action of noradrenaline and angiotensin II.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6376141     DOI: 10.1007/bf00548759

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine.

Authors:  J D Peuler; G A Johnson
Journal:  Life Sci       Date:  1977-09-01       Impact factor: 5.037

2.  [Clinical experimental studies on the blood pressure reducing effect of verapamil].

Authors:  W D Brittinger; A Schwarzbeck; K W Wittenmeier; W D Twittenhoff; B Stegaru; W Huber; R W Ewald; G E von Henning; M Fabricius; M Strauch
Journal:  Dtsch Med Wochenschr       Date:  1970-09-11       Impact factor: 0.628

3.  Comparison of acute effects of nifedipine in normotensive and hypertensive man.

Authors:  O Lederballe Pedersen; N J Christensen; K D Rämsch
Journal:  J Cardiovasc Pharmacol       Date:  1980 Jul-Aug       Impact factor: 3.105

Review 4.  Alpha 1- and alpha 2-adrenoceptors: pharmacology and clinical implications.

Authors:  K Starke; J R Docherty
Journal:  J Cardiovasc Pharmacol       Date:  1981       Impact factor: 3.105

5.  Impairment by nifedipine of vasopressor responses to stimulation of postsynaptic alpha 2-adrenoreceptors in ganglion--blocked rabbits. Further evidence for the selective inhibition of postsynaptic alpha 2-adrenoreceptor-induced pressor responses by calcium antagonists.

Authors:  J C Van Meel; K De Zoeten; P B Timmermans; P A Van Zwieten
Journal:  J Auton Pharmacol       Date:  1982-03

6.  Vascular smooth muscle contraction initiated by postsynaptic alpha 2-adrenoceptor activation is induced by an influx of extracellular calcium.

Authors:  J C Van Meel; A De Jonge; H O Kalkman; B Wilffert; P B Timmermans; P A Van Zwieten
Journal:  Eur J Pharmacol       Date:  1981-01-16       Impact factor: 4.432

7.  Nifedipine, a new antihypertensive with rapid action.

Authors:  M Guazzi; M T Olivari; A Polese; C Fiorentini; F Magrini; P Moruzzi
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

8.  Hyperkinetic heart syndrome: the role of the sympathetic nervous system.

Authors:  H Hörtnagl; D Magometschnigg; J Prager
Journal:  Cardiology       Date:  1982       Impact factor: 1.869

9.  Acute and chronic effects of nifedipine on plasma renin activity and plasma adrenaline and noradrenaline in controls and hypertensive patients.

Authors:  L Corea; N Miele; M Bentivoglio; E Boschetti; E Agabiti-Rosei; G Muiesan
Journal:  Clin Sci (Lond)       Date:  1979-12       Impact factor: 6.124

10.  Hypotensive activity of calcium entry blockers in rats. Relationship with depression of alpha 2-adrenoceptor-mediated vasopressor responses.

Authors:  J C Van Meel; P B Timmermans; P A Van Zwieten
Journal:  Eur J Pharmacol       Date:  1983-08-19       Impact factor: 4.432

View more
  4 in total

Review 1.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 2.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

3.  The dose dependency of the alpha-adrenoceptor antagonist and beta-adrenoceptor partial agonist activity of dilevalol and labetalol in man.

Authors:  T C Tham; J P McKaigue; S Guy; R G Shanks; J G Riddell
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

Review 4.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.